AR050615A1 - Composiciones farmaceuticas para la administracion oral - Google Patents
Composiciones farmaceuticas para la administracion oralInfo
- Publication number
- AR050615A1 AR050615A1 ARP050103558A ARP050103558A AR050615A1 AR 050615 A1 AR050615 A1 AR 050615A1 AR P050103558 A ARP050103558 A AR P050103558A AR P050103558 A ARP050103558 A AR P050103558A AR 050615 A1 AR050615 A1 AR 050615A1
- Authority
- AR
- Argentina
- Prior art keywords
- granules
- therapeutic compound
- moisture sensitive
- mixture
- fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formas de dosis orales solidas incluyen gránulos de fusion de un compuesto terapéutico sensible a la humedad y un componente de fusion hidrofobico. Los gránulos de fusion protegen mejor al compuesto terapéutico de la degradacion hidrolítica. Tales formas de dosis orales solidas también poseen características de liberacion inmedita más que asociadas con productos de fármacos de liberacion extendida o liberacion controlada. Reivindicacion 8: La composicion farmacéutica de acuerdo con la reivindicacion 1, en donde dicho compuesto terapéutico sensible a la humedad es una 2-cianopirrolidina N-(glicilo substituida) o una sal farmacéuticamente aceptable del mismo. Reivindicacion 9: La composicion farmacéutica de acuerdo con la reivindicacion 8, en donde dicha 2-cianopirrolidina N-(glicilo substituida) tiene la formula (1). Reivindicacion 12: Un procedimiento para hacer gránulos que comprende los pasos de: (a) formar una mezcla de un compuesto terapéutico sensible a la humedad con al menos un componente de fusion hidrofobico; (b) calentar dicha mezcla a una temperatura substancialmente cerca del rango de fusion de dicho componente de fusion hidrofobico; (c) granular la mezcla bajo esfuerzo cortante para formar dichos gránulos; y (d) enfriar dichos gránulos a temperatura ambiente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60532704P | 2004-08-27 | 2004-08-27 | |
| US61682804P | 2004-10-07 | 2004-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050615A1 true AR050615A1 (es) | 2006-11-08 |
Family
ID=35447883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103558A AR050615A1 (es) | 2004-08-27 | 2005-08-25 | Composiciones farmaceuticas para la administracion oral |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20080050443A1 (es) |
| EP (2) | EP3087975A1 (es) |
| JP (1) | JP5147399B2 (es) |
| KR (8) | KR20220061249A (es) |
| CN (1) | CN101010068B (es) |
| AR (1) | AR050615A1 (es) |
| AU (1) | AU2005276583B2 (es) |
| BR (1) | BRPI0514682B8 (es) |
| CA (1) | CA2575499A1 (es) |
| DK (1) | DK1786401T3 (es) |
| ES (1) | ES2647671T3 (es) |
| HU (1) | HUE034653T2 (es) |
| MX (1) | MX2007002253A (es) |
| MY (1) | MY144297A (es) |
| PE (1) | PE20060652A1 (es) |
| PL (1) | PL1786401T3 (es) |
| PT (1) | PT1786401T (es) |
| RU (1) | RU2383332C2 (es) |
| SI (1) | SI1786401T1 (es) |
| TW (1) | TWI402082B (es) |
| WO (1) | WO2006021455A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE039902T2 (hu) | 2004-01-20 | 2019-02-28 | Novartis Ag | Közvetlenül préselt formula és eljárás |
| CN1918119B (zh) | 2004-02-05 | 2011-08-31 | 杏林制药株式会社 | 双环酯类衍生物 |
| AR050615A1 (es) | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| JP5101489B2 (ja) * | 2006-03-08 | 2012-12-19 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
| WO2007128801A1 (en) * | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
| ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
| DE102008020701A1 (de) * | 2008-04-24 | 2009-10-29 | Bayer Technology Services Gmbh | Formulierung mit reduzierter Hygroskopizität |
| EP2322499A4 (en) | 2008-08-07 | 2011-12-21 | Kyorin Seiyaku Kk | PROCESS FOR PRODUCING A BICYCLOÝ2.2.2¨OCTYLAMINE DERIVATIVE |
| US20110152342A1 (en) * | 2008-08-14 | 2011-06-23 | Hiroshi Uchida | Stabilized pharmaceutical composition |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| RU2011142829A (ru) | 2009-03-27 | 2013-05-10 | Киорин Фармасьютикал Ко., Лтд. | Препарат матричного типа с пролонгированным высвобождением, содержащий базисную добавку |
| JP2011057586A (ja) * | 2009-09-08 | 2011-03-24 | Kyorin Pharmaceutical Co Ltd | ｐＨ非依存性マトリックス型徐放性製剤 |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| US9071358B2 (en) | 2012-06-21 | 2015-06-30 | Qualcomm Incrorporated | Repeater fiber-coax units |
| US8989577B2 (en) | 2012-06-21 | 2015-03-24 | Qualcomm Incorporated | Methods and systems for implementing time-division duplexing in the physical layer |
| US9363017B2 (en) | 2012-07-06 | 2016-06-07 | Qualcomm Incorporated | Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface |
| JP6283316B2 (ja) * | 2012-10-26 | 2018-02-21 | 株式会社三和化学研究所 | アナグリプチン含有固形製剤 |
| US10369108B2 (en) * | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| CN104274408A (zh) * | 2013-07-10 | 2015-01-14 | 北京科信必成医药科技发展有限公司 | 一种熔融包衣的速释药物微粒及其制备方法 |
| US20150366813A1 (en) * | 2014-06-20 | 2015-12-24 | Banner Life Sciences Llc | Liquid-filled immediate release soft gelatin capsules |
| PL3512505T3 (pl) | 2016-09-16 | 2023-08-07 | Galenicum Health S.L.U. | Farmaceutyczne kompozycje wildagliptyny |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109770A0 (en) | 1993-05-29 | 1994-11-28 | Smithkline Beecham Corp | Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby |
| WO1995005808A1 (en) * | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
| ATE212224T1 (de) * | 1993-11-23 | 2002-02-15 | Euro Celtique Sa | Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US20020142037A1 (en) | 1996-10-01 | 2002-10-03 | Nabil Farah | Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix |
| WO1998018763A1 (fr) | 1996-10-25 | 1998-05-07 | Tanabe Seiyaku Co., Ltd. | Derives de tetrahydroisoquinoline |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| ES2236943T3 (es) | 1997-09-19 | 2005-07-16 | Shire Laboratories Inc. | Perlas de disolucion solida. |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US20020015730A1 (en) | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
| IL157179A0 (en) | 2001-02-02 | 2004-02-08 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| AU2003262059A1 (en) | 2002-09-11 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
| NZ538897A (en) | 2002-10-18 | 2007-02-23 | Merck & Co Inc | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004037181A2 (en) | 2002-10-23 | 2004-05-06 | Bristol-Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| AR050615A1 (es) | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
-
2005
- 2005-08-25 AR ARP050103558A patent/AR050615A1/es not_active Application Discontinuation
- 2005-08-25 PE PE2005000979A patent/PE20060652A1/es not_active Application Discontinuation
- 2005-08-26 WO PCT/EP2005/009252 patent/WO2006021455A1/en active Application Filing
- 2005-08-26 KR KR1020227013566A patent/KR20220061249A/ko active Application Filing
- 2005-08-26 PL PL05775067T patent/PL1786401T3/pl unknown
- 2005-08-26 EP EP16169370.0A patent/EP3087975A1/en not_active Ceased
- 2005-08-26 KR KR1020207019819A patent/KR20200087870A/ko not_active Application Discontinuation
- 2005-08-26 BR BRPI0514682A patent/BRPI0514682B8/pt active IP Right Grant
- 2005-08-26 KR KR1020167032323A patent/KR20160136465A/ko active Search and Examination
- 2005-08-26 KR KR1020197001094A patent/KR20190006612A/ko not_active Application Discontinuation
- 2005-08-26 TW TW094129377A patent/TWI402082B/zh not_active IP Right Cessation
- 2005-08-26 AU AU2005276583A patent/AU2005276583B2/en not_active Ceased
- 2005-08-26 CN CN2005800289311A patent/CN101010068B/zh not_active Expired - Fee Related
- 2005-08-26 DK DK05775067.1T patent/DK1786401T3/da active
- 2005-08-26 KR KR1020177024422A patent/KR20170103039A/ko not_active Application Discontinuation
- 2005-08-26 MX MX2007002253A patent/MX2007002253A/es active IP Right Grant
- 2005-08-26 JP JP2007528755A patent/JP5147399B2/ja active Active
- 2005-08-26 KR KR1020077004461A patent/KR20070049646A/ko active Search and Examination
- 2005-08-26 RU RU2007110953/15A patent/RU2383332C2/ru active
- 2005-08-26 KR KR1020167002363A patent/KR20160017123A/ko not_active Application Discontinuation
- 2005-08-26 MY MYPI20054015A patent/MY144297A/en unknown
- 2005-08-26 HU HUE05775067A patent/HUE034653T2/hu unknown
- 2005-08-26 PT PT57750671T patent/PT1786401T/pt unknown
- 2005-08-26 SI SI200532179T patent/SI1786401T1/sl unknown
- 2005-08-26 EP EP05775067.1A patent/EP1786401B1/en active Active
- 2005-08-26 CA CA002575499A patent/CA2575499A1/en not_active Abandoned
- 2005-08-26 ES ES05775067.1T patent/ES2647671T3/es active Active
- 2005-08-26 KR KR1020137009959A patent/KR101613775B1/ko active IP Right Grant
- 2005-08-26 US US11/573,658 patent/US20080050443A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050615A1 (es) | Composiciones farmaceuticas para la administracion oral | |
| MX2022014458A (es) | Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo. | |
| ES2593582T3 (es) | Formulación de comprimido recubierto y método | |
| ES2548228T3 (es) | Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio | |
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| HRP20230052T1 (hr) | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| US20170183359A1 (en) | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes | |
| HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
| CN110664816A (zh) | Seca抑制剂以及其制备和使用方法 | |
| SA112330689B1 (ar) | صيغة كبسولات تشتمل على مونتليوكاست وليڤوستيريزين | |
| EA201490477A1 (ru) | Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина | |
| ECSP088457A (es) | Compuestos de benzamida útiles como inhibidores de la histona deacetilasa | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| NO20084065L (no) | Hurtig frigivelses paracetamol tabletter | |
| EA201171109A1 (ru) | Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия | |
| WO2022125616A8 (en) | Dialkyl tryptamines and their therapeutic uses | |
| FI3769765T3 (fi) | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus | |
| JP6168673B2 (ja) | アリールアルキルアミン化合物含有医薬組成物 | |
| ES2235383T3 (es) | Beta-alaninas sustituidas. | |
| CO5640071A2 (es) | Composiciones farmaceuticas de atorvastatina | |
| EA200801634A1 (ru) | Твердая фармацевтическая композиция, содержащая ирбесартан | |
| CO6280494A2 (es) | Composiciones que comprenden euphorbia prostrata y procesos de preparacion de las mismas | |
| RU2008147668A (ru) | Способ получения фармацевтических композиций посредством прессования нагреваемыми роликами | |
| CL2004000779A1 (es) | Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |